Reality Check on Immune Globulin (PID)
Market access for immune globulin (PID) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 54% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In July 2019, the FDA approved Grifols’ Xembify (immune globulin subcutaneous human-klhw) to treat primary humoral immunodeficiency disease in people at least two years old. Dosing and dosing intervals for the subcutaneous infusion are based on a patient’s serum IgG trough level and weight
- Key Findings: Few plans have shifted towards specialty pharmacy procurement for immunoglobulin products. Since CMS allowed a step therapy in Medicare Part B in 2019, many plans implemented a step therapy strategy that includes immunoglobulin therapy
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.